ENSCEnsysce Biosciences, Inc.

Nasdaq ensysce.com


$ 0.39 $ -0.01 (-2.5 %)    

Tuesday, 20-Aug-2024 10:51:37 EDT
QQQ $ 480.15 $ -1.01 (-0.21 %)
DIA $ 408.54 $ -0.55 (-0.13 %)
SPY $ 558.65 $ -0.91 (-0.16 %)
TLT $ 98.68 $ 0.78 (0.8 %)
GLD $ 232.46 $ 0.85 (0.37 %)
$ 0.4075
$ 0.39
$ 0.38 x 100
-- x --
$ 0.39 - $ 0.39
$ 0.36 - $ 2.06
84,223
na
3.53M
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-14-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-30-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-31-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
14 06-08-2021 03-31-2021 10-Q
15 03-15-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-07-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-10-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-07-2019 03-31-2019 10-Q
23 03-11-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-01-2018 06-30-2018 10-Q
26 05-03-2018 03-31-2018 10-Q
27 03-09-2018 12-31-2017 10-K
28 01-09-2018 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 watching-ensysce-biosciences-zacks-small-cap-research-gives-stock-1725-price-valuation

https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_08152024_ENSC_Sorensen.pdf

 ensysce-biosciences-q2-eps-022-beats-039-estimate-sales-18180k-miss-30000k-estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $...

 ensysce-biosciences-regains-nasdaq-compliance

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company d...

 ensysce-biosciences-renews-collaboration-with-quotient-sciences-to-undertake-the-study-pf614-mpar-102-to-examine-and-evaluate-the-full-commercial-dose-range-of-the-pf614-mpar-drug-product

New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPARSAN DIEGO, CA / ACCE...

 ensysce-biosciences-q1-2024-gaap-eps-055-beats-090-estimate-sales-305722k-miss-400000k-estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $...

 ensysce-biosciences-q4-eps-113-misses-087-estimate-sales-51503k-beat-39000k-estimate

Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of...

 ensysce-biosciences-announces-the-co-may-continue-its-listing-on-the-nasdaq-capital-market-tier-with-an-extension-to-may-13-2024-in-order-to-demonstrate-compliance-with-the-equity-requirement-in-listing-rule-5550b1

Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to ...

 ensysce-biosciences-receives-fda-guidance-for-pf614-mpar-program

The meeting focused on the Company's non-clinical program for the combination product that is designed for the treatment of...

 why-amd-shares-are-trading-lower-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD rep...

Core News & Articles

ENSC: 92% | Ensysce Biosciences Reports Completion Of A Constructive End Of Phase 2 Meeting With FDA Regarding Its Lead 'Ne...

 ensysce-biosciences-reports-completion-of-a-constructive-end-of-phase-2-meeting-with-fda-regarding-its-lead-next-generation-analgesic-pf614-phase-3-program-expected-to-begin-enrollment-in-mid-2024

"We are appreciative of the guidance provided by the FDA to help us properly position PF614 as we progress through clinical...

 ensysce-biosciences-to-present-oral-overdose-protection-for-opioids-at-the-5th-annual-nih-heal-meeting

Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC), a clinical-stage biotech company applyin...

 why-blackberry-shares-are-trading-lower-by-over-17-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION